Q3 EPS Estimate for Medicus Pharma Decreased by Analyst

Medicus Pharma Ltd (NASDAQ:MDCX) – Equities researchers at Brookline Capital Markets reduced their Q3 2026 EPS estimates for shares of Medicus Pharma in a research note issued on Friday, August 14th. Brookline Capital Markets analyst K. Raja now forecasts that the company will earn ($0.16) per share for the quarter, down from their prior forecast of ($0.09). The consensus estimate for Medicus Pharma’s current full-year earnings is ($0.51) per share. Brookline Capital Markets also issued estimates for Medicus Pharma’s Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.67) EPS, FY2027 earnings at ($0.59) EPS and FY2028 earnings at ($0.54) EPS.

MDCX has been the topic of a number of other research reports. D. Boral Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Medicus Pharma in a report on Monday, April 20th. Alliance Global Partners reiterated a “buy” rating on shares of Medicus Pharma in a research note on Monday. Roth Capital started coverage on shares of Medicus Pharma in a report on Tuesday, April 21st. They set a “buy” rating on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Medicus Pharma in a report on Wednesday, July 8th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $9.00.

Medicus Pharma Stock Performance

Shares of NASDAQ MDCX opened at $0.26 on Tuesday. Medicus Pharma has a 1 year low of $0.25 and a 1 year high of $3.05. The stock has a fifty day moving average price of $0.37 and a two-hundred day moving average price of $0.53. The firm has a market cap of $16.43 million, a P/E ratio of -0.11 and a beta of 0.11.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08).

Hedge Funds Weigh In On Medicus Pharma

A number of institutional investors have recently made changes to their positions in the business. Armistice Capital LLC bought a new stake in Medicus Pharma during the 4th quarter valued at approximately $2,771,000. Private Advisor Group LLC raised its stake in Medicus Pharma by 36.8% during the 1st quarter. Private Advisor Group LLC now owns 240,055 shares of the company’s stock valued at $110,000 after purchasing an additional 64,560 shares during the last quarter. Jane Street Group LLC bought a new stake in Medicus Pharma in the 4th quarter valued at $92,000. Wilmington Savings Fund Society FSB grew its position in Medicus Pharma by 100.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock worth $78,000 after purchasing an additional 25,622 shares during the last quarter. Finally, May Hill Capital LLC raised its position in shares of Medicus Pharma by 100.0% during the fourth quarter. May Hill Capital LLC now owns 35,622 shares of the company’s stock valued at $55,000 after buying an additional 17,811 shares during the last quarter.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.